Philip Philip

4.6k total citations
23 papers, 480 citations indexed

About

Philip Philip is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Philip Philip has authored 23 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in Philip Philip's work include Pancreatic and Hepatic Oncology Research (7 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Philip Philip is often cited by papers focused on Pancreatic and Hepatic Oncology Research (7 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Philip Philip collaborates with scholars based in United States, Spain and United Kingdom. Philip Philip's co-authors include Andrew M. Lowy, Robert Marsh, Alan P. Venook, Mitchell C. Posner, Joseph M. Herman, Steven R. Alberts, Peter W. T. Pisters, Qian Shi, Jordan Berlin and Syed A. Ahmad and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and Cancer Research.

In The Last Decade

Philip Philip

21 papers receiving 476 citations

Peers

Countries citing papers authored by Philip Philip

Since Specialization

Citations

This map shows the geographic impact of Philip Philip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Philip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Philip more than expected).

Fields of papers citing papers by Philip Philip

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Philip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Philip. The network helps show where Philip Philip may publish in the future.

Co-authorship network of co-authors of Philip Philip

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Philip. A scholar is included among the top collaborators of Philip Philip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Philip. Philip Philip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deciphering the metabolic regulation of immunosuppressive CD11b+Gr1+ myeloid cells in epithelial ovarian cancer. 2024 ·The Journal of Immunology ·(unknown), (unknown), (unknown), Miriana Hijaz, Radhika Gogoi, Philip Philip, Adnan Munkarah, Shailendra Giri, Ramandeep Rattan	0
2	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation 2021 ·JCO Oncology Practice ·Cathy Eng, Emerson Y. Chen, Jane E. Rogers, Mark A. Lewis, Jonathan Strosberg, Ramya Thota, Smitha Krishnamurthi, Paul E. Oberstein, (unknown), Gary L. Buchschacher, Sandip Pravin Patel, Davendra Sohal, Taymeyah Al‐Toubah, Philip Philip, Arvind Dasari, (unknown), Stacey Stein	6
3	Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS 2021 ·Cells ·Emil Lou, Joanne Xiu, Yasmine Baca, Andrew C. Nelson, Benjamin A. Weinberg, Muhammad Shaalan Beg, Mohamed E. Salem, Heinz‐Josef Lenz, Philip Philip, Wafik S. El‐Deiry, W. Michael Korn	8
4	Abstract PO-024: Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiotherapy 2021 ·Cancer Research ·William A. Hall, Husain Yar Khan, Mandana Kamgar, Susan Tsai, Kathleen K. Christians, Douglas B. Evans, Philip Philip, Callisia N. Clarke, Ben George, Beth Erickson, Asfar S. Azmi	1
5	Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center 2019 ·Journal of Gastrointestinal Cancer ·(unknown), (unknown), (unknown), (unknown), Paul H. Naylor, Philip Philip, Murray N. Ehrinpreis, Milton G. Mutchnick	2
6	Abstract B15: Therapeutic potential of targeting amino acid metabolism in pancreatic cancer 2019 ·Cancer Research ·Martín E. Fernández-Zapico, Dae Won Kim, Philip Philip, Alexander G. Vandell, Jonathan Eckard, Ron Korn, Giuseppe Del Priore, Diane M. Simeone	2
7	AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions 2019 ·HepatoBiliary Surgery and Nutrition ·Milind Javle, Robin Kate Kelley, Sameek Roychowdhury, Karl Weiss, Ghassan K. Abou‐Alfa, Teresa Macarulla, Saeed Sadeghi, Dirk Waldschmidt, Andrew X. Zhu, Lipika Goyal, Mitesh J. Borad, Wei Peng Yong, Ivan Borbath, Anthony B. El-Khoueiry, Philip Philip, Susan Moran, Yining Ye, (unknown), Nancy Lewis, Tanios Bekaii‐Saab	16
8	A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer 2017 ·Annals of Oncology ·Vincent J. Picozzi, Vaibhav Sahai, Diane M. Simeone, (unknown), Allyson J. Ocean, Philip Philip, (unknown), Aparna Kalyan, Michael S. Ondovik, (unknown), Chrystal U. Louis	1
9	Molecular variations between small bowel adenocarcinomas (SBAs), right-sided colon cancers (RT-Colon), and gastroesophageal cancers (GEC) 2017 ·Annals of Oncology ·Mohamed E. Salem, Heinz‐Josef Lenz, Anthony F. Shields, Joanne Xiu, Tabari M. Baker, Jimmy J. Hwang, Philip Philip, John L. Marshall	2
10	Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer 2017 ·Cancer Chemotherapy and Pharmacology ·Heinz‐Josef Lenz, Philip Philip, Mark Saunders, Tatjana Kolevska, (unknown), Leslie Samuel, Shailesh Bondarde, (unknown), Mary Tagliaferri, Ute Hoch, Alison L. Hannah, (unknown)	7
11	P-272 The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC) 2016 ·Annals of Oncology ·Pascal Hammel, Jill Lacy, Fabienne Portales, (unknown), (unknown), (unknown), Fernando Rivera, (unknown), Eric Terrebonne, (unknown), (unknown), Jamil Asselah, (unknown), (unknown), L. Kayitalire, Philip Philip	1
12	P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study 2016 ·Annals of Oncology ·(unknown), (unknown), Vaibhav Sahai, Diane M. Simeone, (unknown), Philip Philip, (unknown), Aparna Kalyan, (unknown), (unknown), (unknown)	4
13	The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma 2016 ·Journal of Clinical Medicine ·Maria Diab, Irfana Muqbil, Ramzi M. Mohammad, Asfar S. Azmi, Philip Philip	27
14	Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer 2015 ·Acta Oncologica ·Talha Shaikh, Mark Zaki, M.M. Dominello, Elizabeth A. Handorf, André Konski, Steven J. Cohen, Anthony F. Shields, Philip Philip, Joshua E. Meyer	10
15	Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT) 2015 ·Gastroenterology ·Margaret A. Tempero, Dana B. Cardin, Andrew V. Biankin, David Goldstein, Malcolm Moore, Eileen M. O’Reilly, Philip Philip, Hanno Riess, Teresa Macarulla, Lotus Yung, Mingyu Li, Brian Lu	1
16	Conventional risk factors for myocardial infarction in the Maltese population - results from the Maltese Acute Myocardial Infarction (MAMI) study 2014 ·International Journal of Pharmaceutics ·(unknown), Philip Philip, (unknown), Josanne Vassallo, Catharina Jacoba Maria Doggen, Rosienne Farrugia, Stephanie Bezzina Wettinger	0
17	Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer 2014 ·Radiotherapy and Oncology ·André Konski, Joshua E. Meyer, Michael C. Joiner, Michael J. Hall, Philip Philip, Anthony F. Shields, Erin McSpadden, Minsig Choi, (unknown), (unknown), Neal J. Meropol, Terrence P. Cescon, Steven J. Cohen	11
18	Abstract 5589: Molecular diagnostic, prognostic and therapeutic role of mir-221 in pancreatic cancer 2014 ·Cancer Research ·Seema Sethi, (unknown), (unknown), Shadan Ali, Priscila Gonçalves, (unknown), Philip Philip, Yiwei Li	1
19	Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design 2013 ·Annals of Surgical Oncology ·Matthew H. G. Katz, Robert Marsh, Joseph M. Herman, Qian Shi, (unknown), Alan P. Venook, Hedy L. Kindler, Steven R. Alberts, Philip Philip, Andrew M. Lowy, Peter W. T. Pisters, Mitchell C. Posner, Jordan Berlin, Syed A. Ahmad	245
20	Expression of Inflammatory Modulator COX-2 in Pancreatic Ductal Adenocarcinoma and Its Relationship to Pathologic and Clinical Parameters 2001 ·American Journal of Clinical Oncology ·Kambiz Merati, Mir S. Siadaty, Aleodor A. Andea, Fazlul H. Sarkar, Edgar Ben‐Josef, Ramzi M. Mohammad, Philip Philip, Anthony F. Shields, (unknown), David J. Grignon, Volkan Adsay	67

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact